97 related articles for article (PubMed ID: 23827726)
1. Efficacy and safety of AZD1981, a CRTH2 receptor antagonist, in patients with moderate to severe COPD.
Snell N; Foster M; Vestbo J
Respir Med; 2013 Nov; 107(11):1722-30. PubMed ID: 23827726
[TBL] [Abstract][Full Text] [Related]
2. Two Phase II randomized trials on the CRTh2 antagonist AZD1981 in adults with asthma.
Kuna P; Bjermer L; Tornling G
Drug Des Devel Ther; 2016; 10():2759-70. PubMed ID: 27621597
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of the CRTh2 antagonist AZD1981 as add-on therapy to inhaled corticosteroids and long-acting β
Bateman ED; O'Brien C; Rugman P; Luke S; Ivanov S; Uddin M
Drug Des Devel Ther; 2018; 12():1093-1106. PubMed ID: 29765200
[TBL] [Abstract][Full Text] [Related]
4. Effects of an Oral CRTh2 Antagonist (AZD1981) on Eosinophil Activity and Symptoms in Chronic Spontaneous Urticaria.
Oliver ET; Chichester K; Devine K; Sterba PM; Wegner C; Vonakis BM; Saini SS
Int Arch Allergy Immunol; 2019; 179(1):21-30. PubMed ID: 30879003
[TBL] [Abstract][Full Text] [Related]
5. Safety and efficacy of dual bronchodilation with QVA149 in COPD patients: the ENLIGHTEN study.
Dahl R; Chapman KR; Rudolf M; Mehta R; Kho P; Alagappan VK; Chen H; Banerji D
Respir Med; 2013 Oct; 107(10):1558-67. PubMed ID: 23867808
[TBL] [Abstract][Full Text] [Related]
6. Tolerability and efficacy of inhaled AZD4818, a CCR1 antagonist, in moderate to severe COPD patients.
Kerstjens HA; Bjermer L; Eriksson L; Dahlström K; Vestbo J
Respir Med; 2010 Sep; 104(9):1297-303. PubMed ID: 20466530
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of once-daily umeclidinium/vilanterol 62.5/25 mcg in COPD.
Donohue JF; Maleki-Yazdi MR; Kilbride S; Mehta R; Kalberg C; Church A
Respir Med; 2013 Oct; 107(10):1538-46. PubMed ID: 23830094
[TBL] [Abstract][Full Text] [Related]
8. Long-term safety of glycopyrrolate: A randomized study in patients with moderate-to-severe COPD (GEM3).
Mahler DA; Gifford AH; Satti A; Jessop N; Eckert JH; D'Andrea P; Mota F; Banerjee R
Respir Med; 2016 Jun; 115():39-45. PubMed ID: 27215502
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of twice-daily glycopyrrolate in patients with stable, symptomatic COPD with moderate-to-severe airflow limitation: the GEM1 study.
LaForce C; Feldman G; Spangenthal S; Eckert JH; Henley M; Patalano F; D'Andrea P
Int J Chron Obstruct Pulmon Dis; 2016; 11():1233-43. PubMed ID: 27354782
[TBL] [Abstract][Full Text] [Related]
10. A randomised trial of fluticasone furoate/vilanterol (50/25 μg; 100/25 μg) on lung function in COPD.
Kerwin EM; Scott-Wilson C; Sanford L; Rennard S; Agusti A; Barnes N; Crim C
Respir Med; 2013 Apr; 107(4):560-9. PubMed ID: 23352226
[TBL] [Abstract][Full Text] [Related]
11. Effects of indacaterol/glycopyrronium (QVA149) on lung hyperinflation and physical activity in patients with moderate to severe COPD: a randomised, placebo-controlled, crossover study (The MOVE Study).
Watz H; Mailänder C; Baier M; Kirsten A
BMC Pulm Med; 2016 Jun; 16(1):95. PubMed ID: 27301417
[TBL] [Abstract][Full Text] [Related]
12. Exploring the insulin secretory properties of the PGD2-GPR44/DP2 axis in vitro and in a randomized phase-1 trial of type 2 diabetes patients.
Skrtic S; Tyrberg B; Broberg M; Ericsson H; Schnecke V; Kjaer M; Hompesch M; Andersson EM; Ryberg E; Aivazidis A; Wennberg Huldt C; Löfgren L; Morrow L; Parkinson J; Rydén-Bergsten T; Watkins E; Sörhede Winzell M
PLoS One; 2018; 13(12):e0208998. PubMed ID: 30557325
[TBL] [Abstract][Full Text] [Related]
13. Safety and efficacy of the once-daily anticholinergic BEA2180 compared with tiotropium in patients with COPD.
Abrahams R; Moroni-Zentgraf P; Ramsdell J; Schmidt H; Joseph E; Karpel J
Respir Med; 2013 Jun; 107(6):854-62. PubMed ID: 23490224
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of glycopyrrolate/eFlow
Kerwin E; Donohue JF; Goodin T; Tosiello R; Wheeler A; Ferguson GT
Respir Med; 2017 Nov; 132():238-250. PubMed ID: 28838685
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and tolerability of indacaterol 75 μg once daily in patients aged ≥40 years with chronic obstructive pulmonary disease: results from 2 double-blind, placebo-controlled 12-week studies.
Kerwin EM; Gotfried MH; Lawrence D; Lassen C; Kramer B
Clin Ther; 2011 Dec; 33(12):1974-84. PubMed ID: 22177371
[TBL] [Abstract][Full Text] [Related]
16. Single inhaler triple therapy versus inhaled corticosteroid plus long-acting β2-agonist therapy for chronic obstructive pulmonary disease (TRILOGY): a double-blind, parallel group, randomised controlled trial.
Singh D; Papi A; Corradi M; Pavlišová I; Montagna I; Francisco C; Cohuet G; Vezzoli S; Scuri M; Vestbo J
Lancet; 2016 Sep; 388(10048):963-73. PubMed ID: 27598678
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of a new once-daily long-acting inhaled beta2-agonist indacaterol versus twice-daily formoterol in COPD.
Dahl R; Chung KF; Buhl R; Magnussen H; Nonikov V; Jack D; Bleasdale P; Owen R; Higgins M; Kramer B;
Thorax; 2010 Jun; 65(6):473-9. PubMed ID: 20522841
[TBL] [Abstract][Full Text] [Related]
18. Safety and tolerability of an oral MMP-9 and -12 inhibitor, AZD1236, in patients with moderate-to-severe COPD: a randomised controlled 6-week trial.
Magnussen H; Watz H; Kirsten A; Wang M; Wray H; Samuelsson V; Mo J; Kay R
Pulm Pharmacol Ther; 2011 Oct; 24(5):563-70. PubMed ID: 21624491
[TBL] [Abstract][Full Text] [Related]
19. Nebulized arformoterol in patients with COPD: a 12-week, multicenter, randomized, double-blind, double-dummy, placebo- and active-controlled trial.
Baumgartner RA; Hanania NA; Calhoun WJ; Sahn SA; Sciarappa K; Hanrahan JP
Clin Ther; 2007 Feb; 29(2):261-78. PubMed ID: 17472819
[TBL] [Abstract][Full Text] [Related]
20. A randomized, double-blind, placebo-controlled study of the CRTH2 antagonist OC000459 in moderate persistent asthma.
Barnes N; Pavord I; Chuchalin A; Bell J; Hunter M; Lewis T; Parker D; Payton M; Collins LP; Pettipher R; Steiner J; Perkins CM
Clin Exp Allergy; 2012 Jan; 42(1):38-48. PubMed ID: 21762224
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
